These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14757999)

  • 21. Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions.
    Skripnik KKS; Riekes MK; Pezzini BR; Cardoso SG; Stulzer HK
    AAPS PharmSciTech; 2017 Jul; 18(5):1785-1794. PubMed ID: 27800567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KINETICS STUDY ON KETOPROFEN RELEASE FROM MINI TABLETS AND MULTI-COMPARTMENT SYSTEMS.
    Stawarski T; Sieradzki E; Gałecka E; Binek K
    Acta Pol Pharm; 2016; 73(3):731-7. PubMed ID: 27476291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Product development studies on the tablet formulation of ibuprofen to improve bioavailability.
    Ghosh LK; Ghosh NC; Chatterjee M; Gupta BK
    Drug Dev Ind Pharm; 1998 May; 24(5):473-7. PubMed ID: 9876610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of new topical ketoprofen formulations prepared by drug entrapment in solid lipid matrices.
    Argemí A; Domingo C; de Sousa AR; Duarte CM; García-González CA; Saurina J
    J Pharm Sci; 2011 Nov; 100(11):4783-9. PubMed ID: 21710507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enantioselective release of controlled delivery granules based on molecularly imprinted polymers.
    Suedee R; Srichana T; Rattananont T
    Drug Deliv; 2002; 9(1):19-30. PubMed ID: 11839205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulation of a extended release tablet containing dexibuprofen.
    Yi HG; Chi MH; Kim YI; Woo JS; Park ES
    Arch Pharm Res; 2008 Dec; 31(12):1637-43. PubMed ID: 19099235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and characterization of sustained release ketoprofen entrapped carnauba wax microparticles.
    Oliveira RB; Nascimento TL; Lima EM
    Drug Dev Ind Pharm; 2012 Jan; 38(1):1-11. PubMed ID: 21671838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of membrane type and liquid/liquid phase boundary on in vitro release of ketoprofen from gel formulations.
    Gallagher SJ; Trottet L; Carter TP; Heard CM
    J Drug Target; 2003 Jul; 11(6):373-9. PubMed ID: 14668058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
    Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
    Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new approach for preparing a controlled release ketoprofen tablets by using beeswax.
    Uner M; Gönüllü U; Yener G; Altinkurt T
    Farmaco; 2005 Jan; 60(1):27-31. PubMed ID: 15652365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro release profile of estradiol transdermal therapeutic systems.
    Tymes NW; Shah VP; Skelly JP
    J Pharm Sci; 1990 Jul; 79(7):601-2. PubMed ID: 2398467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fast dispersible/slow releasing ibuprofen tablets.
    Fini A; Bergamante V; Ceschel GC; Ronchi C; de Moraes CA
    Eur J Pharm Biopharm; 2008 May; 69(1):335-41. PubMed ID: 18182280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basic butylated methacrylate copolymer/kappa-carrageenan interpolyelectrolyte complex: preparation, characterization and drug release behaviour.
    Prado HJ; Matulewicz MC; Bonelli P; Cukierman AL
    Eur J Pharm Biopharm; 2008 Sep; 70(1):171-8. PubMed ID: 18583115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring release of ketoprofen enantiomers from biodegradable poly(D,L-lactide-co-glycolide) injectable implants.
    Wang SH; Liang ZH; Zeng S
    Int J Pharm; 2007 Jun; 337(1-2):102-8. PubMed ID: 17296274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.
    Lorier M; Magallanes L; Ibarra M; Guevara N; Vázquez M; Fagiolino P
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):787-793. PubMed ID: 26590950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ion-exchange selectivity of diclofenac, ibuprofen, ketoprofen, and naproxen in ureolyzed human urine.
    Landry KA; Sun P; Huang CH; Boyer TH
    Water Res; 2015 Jan; 68():510-21. PubMed ID: 25462757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Optimization of the matrix formulation of compound Die Da Zhen Tong cataplasm by uniform design].
    Zhang JX; Wang JP; Zhu F; Deng ZJ; Zhao CW
    Zhong Yao Cai; 2011 Jun; 34(6):971-4. PubMed ID: 22017015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.